Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury ...

Hims & Hers Health (NYSE:HIMS) recently saw a significant stock price increase, jumping 140% over the past month. This rise ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% YoY. Check out why I ...

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Hims & Hers Health HIMS is well-positioned for growth as it addresses a vast unmet healthcare market, leveraging a total addressable market of $360M across specialties like mental health ...

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

1 Day HIMS 1.35% DJIA -0.19% S&P 500 -0.32% Retail/Wholesale 0.87% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by ...